Results 1 to 10 of about 34,892 (272)
Progressive supranuclear palsy: new concepts [PDF]
Arquivos de Neuro-Psiquiatria, 2010 Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative disease which affects the brainstem and basal ganglia. Patients present supranuclear ophthalmoplegia, postural instability and mild dementia.
Orlando Graziani Povoas Barsottini +3 more
doaj +7 more sources
Progressive supranuclear palsy [PDF]
Parkinsonism & Related Disorders, 2012 Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy which can manifest clinically in a variety of syndromes. In this review, the classic and most common variant syndrome -PSP-Richardson's syndrome (PSP-RS) -is the focus, with the core clinical features, varying cognitive/motor/neuropsychiatric/sleep manifestations, neuropsychological ...
Loretta, Mazorra, Mary P, Cadogan
core +8 more sources
Understanding fatigue in progressive supranuclear palsy [PDF]
Scientific Reports, 2021 Fatigue is a common and disabling non-motor symptom (NMS) of Parkinson’s disease (PD); however, it has been poorly understood in patients with progressive supranuclear palsy (PSP).
Jong Hyeon Ahn +4 more
doaj +2 more sources
Emerging Hypersexuality in a Patient With Progressive Supranuclear Palsy [PDF]
BJPsych OpenAims: Progressive supranuclear palsy (PSP) typically presents with a constellation of motor symptoms, most commonly with frequent falls and gait disturbances.
Pei Ling Lim, Boon Ceng Chai
doaj +2 more sources
4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy [PDF]
Nature CommunicationsProgressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by abnormal accumulation of the protein tau in the brain, leading to motor and cognitive symptoms that vary between individuals. The reasons for this clinical heterogeneity
Ivan Martinez-Valbuena +21 more
doaj +2 more sources
Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework. [PDF]
J NeurolRyan C +5 more
europepmc +3 more sources
Progressive supranuclear palsy [PDF]
Seminars in Neurology, 2001 Unfortunately, no drug treatment has been shown to benefit patients with progressive supranuclear palsy (PSP) more than modestly or briefly. The multiplicity of neuronal systems and synaptic physiologies that degenerate in this disorder makes a neurotransmitter-specific approach, such as neurotransmitter replacement or reuptake inhibition, unlikely to ...
K, Tawana, D B, Ramsden
openaire +5 more sources
Progressive supranuclear palsy [PDF]
Postgraduate Medical Journal, 2000 Abstract Progressive supranuclear palsy (PSP) or Steele-Richardson-Olszewski syndrome is a neurodegenerative disease of middle and late age. It is under-diagnosed not only by general physicians but also by neurologists. The cause of PSP is not known.
, Lowrey, , Wong
openaire +4 more sources
Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database
Frontiers in Neurology, 2021 Background: Progressive supranuclear palsy is a rare neurodegenerative movement disorder and little is known about its epidemiology.Objective: Estimate age-adjusted prevalence of progressive supranuclear palsy and describe antecedent diagnoses and ...
Emma Viscidi +11 more
doaj +1 more source
Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation. [PDF]
J NeurolKassubek J +6 more
europepmc +3 more sources